ACR70-disease activity score remission achievement from switches between all the available biological agents in rheumatoid arthritis: a systematic review of the literature by Stefano Alivernini et al.
Available online http://arthritis-research.com/content/11/6/R163Open AccessVol 11 No 6Research article
ACR70-disease activity score remission achievement from 
switches between all the available biological agents in 
rheumatoid arthritis: a systematic review of the literature
Stefano Alivernini, Antonella Laria, Elisa Gremese, Angelo Zoli and Gianfranco Ferraccioli
Division of Rheumatology, School of Medicine, Catholic University of the Sacred Heart, Largo F Vito 1, 00168 Rome, Italy
Corresponding author: Gianfranco Ferraccioli, gf.ferraccioli@rm.unicatt.it
Received: 15 Jul 2009 Revisions requested: 20 Aug 2009 Revisions received: 24 Oct 2009 Accepted: 3 Nov 2009 Published: 3 Nov 2009
Arthritis Research & Therapy 2009, 11:R163 (doi:10.1186/ar2848)
This article is online at: http://arthritis-research.com/content/11/6/R163
© 2009  Alivernini et al.; licensee BioMed Central Ltd. 
This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract
Introduction The aim of our analysis was to compare the
gaining of a major response (disease activity score [DAS]
remission or American College of Rheumatology 70%
improvement criteria [ACR70]) by switching between all the
available biological therapies in rheumatoid arthritis.
Methods A systematic review was performed including studies,
published before December 2008, in which a second biological
agent was used and clinical outcomes were evaluated after a
first biological failure.
Results Nine articles were included. Switching from etanercept
and/or infliximab to adalimumab is effective with an ACR70
response ranging from 5% to 33%. Rituximab may be slightly
more effective than switching to a second anti-tumor necrosis
factor-alpha (anti-TNFα), reaching an ACR70 or DAS remission
response in 12% and 9%, respectively. Clinical trials confirmed
the efficacy in switching to abatacept (gain of effect 10.2%).
Tocilizumab allows DAS28 (DAS using 28 joint counts)
remission in 30.1% but ACR70 only in 12.4% of patients
refractory to anti-TNFα.
Conclusions The efficacy of a second biological agent,
irrespective of the mode of action, in reaching an ACR70 or
DAS remission after a first biologic is observed from 5% to 15%
and from 9% to 15.4%, respectively (except in two studies).
Introduction
Three anti-tumor necrosis factor-alpha (anti-TNFα) therapies
are approved for rheumatoid arthritis (RA) by the US Food and
Drug Administration: infliximab (Remicade®), adalimumab
(Humira®), and etanercept (Enbrel®). Two more will come
soon (certolizumab pegol and golimumab). Although similari-
ties clearly predominate when comparing the three available
anti-TNFα agents, a number of clinical differences in efficacy
or safety have been noted [1,2]. First, the half-lives - 3 days for
etanercept, 10 days for infliximab, and 13 days for adalimumab
- may translate into differences in the duration of TNFα neutral-
ization [2]. Also, the two monoclonal antibodies, infliximab and
adalimumab, have very strong affinity for TNFα, increasing the
percentage of neutralized TNFα molecules. In addition, the
complexes formed when monomeric and trimeric soluble and
membrane-associated TNFα molecules bind to the anti-TNFα
agent are far more stable with infliximab and adalimumab than
with etanercept. Finally, the monoclonal antibodies are highly
specific for TNFα, whether soluble or at the membrane level,
whereas etanercept binds to lymphotoxin-α in addition to sol-
uble TNFα, leading to the control of another possible pathoge-
netic pathway. Soluble TNFα binds to the fusion protein,
becoming unable to act on its cellular receptor. Thus, etaner-
cept has a buffering effect on TNFα, and this effect is probably
reversible and does not result in permanent elimination of
TNFα molecules. Furthermore, binding of etanercept to mem-
brane-associated TNFα does not cause cell lysis. Infliximab
and adalimumab can bind two soluble or membrane-associ-
ated TNFα molecules, forming a stable and long-lasting com-
plex and causing cell lysis (for example, macrophages and
some T-cell subsets) or cell function impairments [2]. These
differences may influence the risk of immune responsePage 1 of 7
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greater risk of tuberculosis with infliximab and adalimumab
than with etanercept. Immunogenicity seems extremely weak
for etanercept and adalimumab but higher for infliximab, induc-
ing antibodies to its murine component (human anti-murine
antibodies, or HAMA) and leading to allergic reactions and the
often-seen escape phenomenon [2]. All of these data have led
physicians to treat RA patients who experience treatment fail-
ure with one anti-TNFα agent (due to either inefficacy or toxic-
ity) by switching to a second anti-TNFα agent, although the
clear-cut benefits of switching are unknown because no con-
trolled trial has ever been conducted.
Rituximab, or anti-CD20, is an antibody used in RA, whereas
abatacept is a dimeric fusion soluble protein made of the extra-
cellular part of CTLA-4 present on T cells and Fc of IgG1. It
links CD80/86 on antigen-presenting cells with a higher affin-
ity than CD28, thus preventing the costimulation. Tocilizumab
is a humanized antibody that links both soluble and membra-
nous interleukin-6 receptor. The differences in the mechanism
of action should allow clinicians to rescue patients not fully
responding to a TNFα blocker since a different pathway is tar-
geted; however, a definite analysis of the gain of effect in terms
of disease activity score (DAS) remission or of an American
College of Rheumatology 70% improvement criteria (ACR70)
response - that clearly allows clinicians to identify the crucial
pathway alternative to TNFα - has not been provided. The aim
of this study was to investigate the evidence in the literature
about the efficacy of switching between different biologics in
RA patients.
Materials and methods
We performed a search on MEDLINE, EMBASE, and the
Cochrane Library from inception to December 2008 to identify
all of the available articles. The terms we used were 'arthritis',
'rheumatoid', 'biological agents (infliximab, etanercept, adali-
mumab, rituximab, anakinra, abatacept, tocilizumab)', 'switch
or switching', 'randomized controlled trials', 'multicenter stud-
ies', 'clinical trials phase II', 'clinical trials phase III', and 'clinical
trials phase IV'. We searched even in the abstract databases
of both the European League Against Rheumatism (EULAR)
and the ACR from 1996 to the present in order to identify
unpublished studies. Articles were selected by applying pre-
defined inclusion and exclusion criteria, and their methodolog-
ical quality was graded according to the levels of evidence of
the Centre for Evidence-Based Medicine (Oxford, UK) [3].
The language of the paper was not restricted. References of
the studies were analyzed to find any study that was not
included in the electronic databases. A study was included in
the systematic extraction of the data if (a) it was published
before December 2008, (b) it was about patients with RA, (c)
a biological agent was used and failed according to the clinical
response (DAS using 28 joint counts [DAS28] of greater than
2.6 or EULAR criteria for poor responders), and (d) a second
biological agent was used and clinical outcomes were evalu-
ated. The ACR responses (ACR20, ACR50, and ACR70)
were used as efficacy parameters. During the writing process,
only articles concerning major response, as ACR70 or the
DAS showing disease remission, were included. The extrac-
tion of the data was conducted independently by two
investigators.
Results
After the systematic literature research, nine articles fulfilled
the inclusion criteria and were included in the review. All of the
articles were divided according to the biological agent failed
and switched (Figure 1 and Table 1).
Rate of efficacy (gaining of major responses) in 
etanercept-treated patients who failed treatment with 
infliximab
In a prospective, 12-week, open-label, single-arm, observa-
tional study, Haraoui and colleagues [4] showed the efficacy
of etanercept when infliximab had been ineffective. Twenty-five
RA patients were enrolled; 18 of them discontinued infliximab
because of lack of efficacy, and 22 completed 12 weeks of
etanercept treatment. After 12 weeks of follow-up, 64%
patients achieved at least an ACR20 response and 5%
achieved an ACR70 response. Fifty-nine percent of patients
experienced improvement in Health Assessment Question-
naire (HAQ) score (with a decrease of at least 0.22 in HAQ
score) [4] (3b level of Oxford evidence).
Buch and colleagues [5] analyzed 95 RA patients who failed
infliximab and methotrexate treatment and switched to etaner-
cept. Thirty-four patients never achieved a response to inflixi-
mab (primary non-responders), 38 had an initial response to
infliximab but relapsed (secondary non-responders), and 23
had side effects. After 12 weeks, 38% of patients achieved an
ACR20 response whereas 24% and 15% achieved ACR50
and ACR70 responses, respectively. In the primary non-
responder group, 42%, 30%, and 15% of patients achieved
ACR20, ACR50, and ACR70 responses, respectively; the
rates for the secondary non-responder group were 34%, 21%,
and 14%, respectively. Similar results were obtained even
comparing a moderate or good EULAR score (67% of primary
and 56% of secondary infliximab failures) and DAS28 reduc-
tion [5] (3b level of Oxford evidence).
Rate of efficacy (gaining major responses) in infliximab-
treated patients who failed treatment with etanercept
In a randomized, open-label, clinical trial conducted by Furst
and colleagues [6], 28 RA patients with an inadequate
response to etanercept were randomly assigned to discon-
tinue etanercept and receive infliximab (group 1) or to continue
etanercept (group 2). At week 16, 62% of infliximab-treated
patients achieved an ACR20 response compared with 29% of
etanercept-treated patients, and 30.7% of group 1 achieved
ACR50 compared with 14.3% of group 2. DAS28 values ofPage 2 of 7
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patients compared with 7.1% of etanercept-treated patients.
DAS28 percentage changes from baseline were -30.8 in
group 1 and -16 in group 2. The percentages of patients with
an HAQ score decrease of greater than 0.22 were 61.5% and
14.3% in groups 1 and 2, respectively [6] (3b level of Oxford
evidence).
Rate of efficacy (gaining major responses) in 
adalimumab-treated patients who failed treatment with 
infliximab or etanercept or both
In the ReAct (Research in Active Rheumatoid Arthritis) trial,
Bombardieri and colleagues [7] evaluated the effectiveness
and safety of adalimumab in RA patients who previously dis-
continued TNFα antagonists for any reason. Of 6,610 patients
enrolled in the ReAct trial, 5,711 had never been treated with
an anti-TNFα agent, 591 were previously treated with inflixi-
mab, 188 were treated with etanercept, and 120 were treated
with both TNFα agents. In the infliximab group, 507 patients
underwent adalimumab treatment, and 22% discontinued due
to no response, 51% due to loss of response, and 27% due
to intolerance. In the etanercept group, 151 patients received
adalimumab, and 42% discontinued due to no response, 32%
due to loss of response, and 26% due to intolerance. At week
12, 60% of patients switched to adalimumab had an ACR20
response and 33% had an ACR50 response; 76% had a mod-
erate and 23% had a good EULAR response. In addition, 12%
achieved a DAS28 of less than 2.6 and 13% achieved an
HAQ score of less than 0.5 [7] (2b level of Oxford evidence).
Nikas and colleagues [8] confirmed the previous data showing
that adalimumab has the same efficacy in 25 RA patients naïve
to biological treatment and 24 who had previously used inflixi-
mab. After 1 year of follow-up, clinical improvement was similar
in the two groups: ACR20, ACR50, and ACR70 responses
were achieved by 75%, 50%, and 33% of switchers, respec-
tively [8] (3b level of Oxford evidence).
Rate of efficacy (gaining of major responses) in 
rituximab-treated patients who failed treatment with 
TNFα blockers
In the REFLEX (Randomized Evaluation of Long-Term Efficacy
of Rituximab in RA) trial, Cohen and colleagues [9] evaluated
primary efficacy and safety at 24 weeks in patients with active
RA and an inadequate response to one or more anti-TNFα
agents. Three hundred eleven patients received a course of
rituximab while 209 patients received placebo. At week 24,
ACR20, ACR50, and ACR70 responses were achieved in
51%, 27%, and 12%, respectively, in the group treated with
rituximab compared with 18%, 5%, and 1% in the placebo
group. Rituximab-treated patients showed a trend toward less
progression in radiographic endpoints, and all ACR response
parameters were significantly improved. Clinical improvement
was seen in fatigue, disability, and health-related quality of life
(demonstrated by FACIT-F [Functional Assessment of
Chronic Illness Therapy-Fatigue], HAQ disease index, and SF-
36 [Short Form Health Survey-36] scores, respectively) [9]
(1b level of Oxford evidence). Moreover, as shown by Finckh
and colleagues [10], the switch to rituximab after the failure of
Figure 1
Search strategy tree. RCT, randomized controlled trial.Page 3 of 7
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Rate of efficacy (gaining of major responses) in 
abatacept-treated patients who failed treatment with 
TNFα blockers
In the Abatacept Trial in Treatment of Anti-TNF Inadequate
Responders (ATTAIN), abatacept was studied in RA patients
who failed anti-TNFα therapy. Three hundred ninety-one
patients were followed for 6 months. ACR20, ACR50, and
ACR70 responses were 50.4%, 20.3%, and 10.2% in the
treated group compared with 19.5%, 3.8%, and 1.5% for
those receiving placebo. DAS28 remission rates were 10.0%
in the treated group and 0.8% in the placebo group [11] (1b
level of Oxford evidence).
In the ARRIVE (Abatacept Researched in RA patients with an
Inadequate anti-TNF response to Validate Effectiveness) trial,
which aimed to assess the safety and tolerability in patients
with active RA who had failed up to three anti-TNFα agents,
the mean reduction in DAS28 at 6 months was -2.0 from base-
line. Overall, 22.4% of patients achieved a low disease activity
state and 13.0% achieved remission [12] (1b level of Oxford
evidence).
Rate of efficacy (gaining of major responses) in 
tocilizumab-treated patients who failed treatment with 
anti-TNFα
In the RADIATE (Rheumatoid Arthritis Study in Anti-TNF Fail-
ures) trial, Emery and colleagues [13] recently showed the
improvement in 499 RA patients who had inadequate
response to at least one anti-TNFα antagonist and who were
treated with tocilizumab. DAS28 remission (DAS28 of not
more than 2.6) rates at 24 weeks were clearly dose-related,
being achieved by 30.1%, 7.6%, and 1.6% of 8 mg/kg, 4 mg/
kg, and control groups (P = 0.0001 for 8 mg/kg and P =
0.053 for 4 mg/kg versus control). Both 8 mg/kg (50.0%) and
4 mg/kg (30.4%) groups had a higher rate of ACR20
Table 1
Gain of a major response by switching between different available biological agents in rheumatoid arthritis
Results
Study Number of 
patients
Switch type ACR20 ACR50 ACR70 DAS44 <1.6 or 
DAS28 <2.6
ΔDAS P < 0.05 Evidence levela Strengtha
Anti-TNFα blockers
[3] 25 IFX → ETA 64% 23% 5% - - 3b B
[4] 95 IFX → ETA 38% 24% 15% - 6.46 → 4.97 3b B
[5] 28 ETA → IFX 62% 30.7% - 15.4% 5.2 → 4 3b B
[6] 6,610 ETA/IFX → ADA 60% 33% 13% 12% 31% (-1.9 ± 1.4) 2b B
[7] 25 IFX → ADA 75% 50% 33% - 5.6 → 3.2 3b B
Anti-CD20
[8] 311 Anti-TNFα → 
RTX




[10] 391 Anti-TNFα → 
ABA
50.4% 20.3% 10.2% 10.0% - 1b A
[11] 1,046 Anti-TNFα → 
ABA
- - - 13.0% 56.1% (-2.0) 1b A
Interleukin-6R inhibitor
[12] 499 Anti-TNFα → 
TOC
50.0% 28.8% 12.4% 30.1% - 1b A
aAccording to the levels of evidence of the Centre for Evidence-Based Medicine (Oxford, UK). ΔDAS P <0.05, significant difference in disease 
activity score value before and after switching; ABA, abatacept; ACR20, American College of Rheumatology 20% improvement criteria; ACR50, 
American College of Rheumatology 50% improvement criteria; ACR70, American College of Rheumatology 70% improvement criteria; ADA, 
adalimumab; anti-TNFα, anti-tumor necrosis factor-alpha; DAS28, disease activity score using 28 joint counts; DAS44, disease activity score 
using 44 joint counts; ETA, etanercept; IFX, infliximab; RTX, rituximab; TOC, tocilizumab (8 mg/kg group).Page 4 of 7
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ACR70 responses after 24 weeks were achieved by 28.8%
and 12.4% of patients in the 8 mg/kg group (P < 0.0001 and
P < 0.0002, respectively, versus control) [13] (1b level of
Oxford evidence).
Discussion
Several studies analyzed the efficacy and the gaining of major
responses in RA patients treated with different biological
drugs. Table 1 summarizes the results obtained from our
research. Few studies had strong evidence, mainly evaluating
efficacy in switching from anti-TNFα to new targeted therapies
(rituximab, abatacept, and tocilizumab). The data available
suggest that many of the clinical considerations and decisions
that we adopt rely on less than strong scientific evidence. Cli-
nicians should consider the data we present as a practical
approach in making the everyday decisions to reach the low-
est possible level of clinical activity [14].
The data show that switching from infliximab to etanercept is
effective, with an ACR20 response of between 33% and 64%
according to different studies. Moreover, etanercept seems to
be able to maintain the ACR20 response obtained with inflixi-
mab when the latter biological agent is stopped because of
side effects [15]. Data show that a previous failure with etaner-
cept does not influence the response to infliximab with a reach
of clinical response. Indeed, there is no doubt that a clinical
effect can be reached by switching.
Switching to another biological agent in patients treated with
infliximab is due mainly to a loss of response during treatment,
whereas in patients treated with etanercept, switching is due
to non-response. The effectiveness of adalimumab seems not
to be influenced by previous treatment with infliximab.
In regard to patients treated with a second TNFα inhibitor who
failed the first, data show a continuation rate of a second TNFα
blocker of 73% of switchers after 15 months of follow-up [16].
Switchers to a second anti-TNFα drug seem to have high
treatment rates of continuation, and first drug withdrawal due
to inefficacy is associated with an increased rate of a second
drug withdrawal due to inefficacy but not toxicity; similarly, first
drug withdrawal due to toxicity is associated with an increased
rate of a second drug withdrawal due to toxicity but not ineffi-
cacy. All of these data suggest that a clinical response can be
obtained from switching, but given the high cost of the drug, it
seems questionable to rely on this response value as a way of
treating all poor responders (not reaching low disease activity
or DAS remission). In fact, in terms of major outcomes such as
DAS remission and ACR70, the results are less convincing.
Not more than 5% to 15.4% of the patients overall can be led
to remission. This was confirmed in the last trial with golimu-
mab recently published, that showed the 10% rescue to the
major response [17]. This is clearly disappointing when facing
the first failure.
In clinical practice, it is reasonable to switch from one anti-
TNFα agent to a second one, possibly with a different mecha-
nism of action. It does not appear useful to switch to a third
one [18], but it seems worthwhile to treat patients who are
resistant to this therapeutic approach with other biological
agents, such as anti-CD20, abatacept, or tocilizumab.
Rituximab has been said to be more effective than switching to
an alternative anti-TNFα agent. Moreover, it was demonstrated
that treatment with rituximab may be more effective than
switching to an alternative anti-TNFα agent in RA patients in
whom active disease persisted despite anti-TNFα therapy
[10], even though the difference seems to be really more sta-
tistically than clinically significant. Similar data have been seen
in clinical trials that have confirmed the efficacy of switching to
abatacept from an anti-TNFα agent, thus suggesting that
using a drug with a different mechanism of action may help.
In RA patients who do not respond to the anti-TNFα strategy,
another therapeutic option is tocilizumab with a dose-depend-
ent clinical response with a strong discrepancy between DAS
remission and ACR70. Data suggest that a strong effect on
pain and acute-phase reactants leads to this dissociation.
However, comparing the changes in disease activity and
response to tocilizumab using the Clinical Disease Activity
Index (CDAI) and Simplified Disease Activity Index (SDAI) in
three clinical trials (LITHE, OPTION, and TOWARD), Smolen
and colleagues [19] recently found significant differences in
changes of CDAI and SDAI between treatment with tocilizu-
mab and placebo, with a minimal impact of C-reactive protein
on clinical disease activity measures.
The introduction of anti-TNFα marked the beginning of a new
era in the treatment of RA. Nonetheless, the efficacy of each
biological agent is not similar in all patients, underlying the
need for a drug switch between the agents. Moreover, the
switch to different biological target therapies could be neces-
sary because of the presence of driving cytokines other than
TNFα. In general, an ACR20 can be obtained in 60% or more
of the poor responders to the TNFα blockers, and an ACR70-
DAS remission value can be obtained in roughly 10% to 15%
of the cohorts after the TNFα blockade, with either CD20
depletion or CTLA4 stimulation. The rule of a 10% to 15%
gain of effect after TNFα, the major target, seems to be a good,
but not ideal, perspective for the future of RA. These data
strongly argue for a clear-cut need for biomarkers capable of
identifying, at baseline, which RA patients having different
pathways will be the best responders to some biologics or
poor responders to other biologics. Yet these biomarkers are
not at hand. Furthermore, prescribing a biological agent is an
important decision that can greatly impact the quality of life of
a patient and can be associated with varying medical costs,
owing to differences in routes of administration (depending on
the agent). Etanercept and adalimumab are administered sub-
cutaneously. Both can be self-administered at home, but theyPage 5 of 7
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frequent administration and the risk of pain and local site reac-
tions. Intravenous drugs can be inconvenient for patients with
respect to traveling and taking time off from work for infusions
and also for patients with difficulties regarding intravenous
access. Intravenous administration may use more health care
resources and require infusion rooms and equipment as well
as medical and nursing supervision [20]. Anti-TNFα agents
require a short time of administration to reach their effect, and
anti-CD20 and abatacept have to compete with this very prac-
tical issue that needs to be considered when a choice has to
be made to reach a major response. In addition, the more
frequent administration with some TNFα blockers, required to
better control the disease activity status, should lead to a care-
ful analysis of cost in all of these situations.
Conclusions
The efficacy of different biological agents in selected rand-
omized controlled trial populations is not similar in all patients,
underlying the presence of different pathways driving the
inflammatory process. The rescue to a major response seems
to occur at a rate of 10% to 15% among the various biologics.
Annual costs and administration modalities need to be taken
into account when making therapeutic decisions in non-
responders.
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